Prevention of cisplatin-based chemotherapy-induced delayed nausea and vomiting using triple antiemetic regimens: a mixed treatment comparison

about

Prevention of cisplatin-based chemotherapy-induced delayed nausea and vomiting using triple antiemetic regimens: a mixed treatment comparison

Item

http://www.wikidata.org/entity/Q35970506

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Prevention of cisplatin-based ...... : a mixed treatment comparison

@ast

Prevention of cisplatin-based ...... : a mixed treatment comparison

@en

type

Item

label

Prevention of cisplatin-based ...... : a mixed treatment comparison

@ast

Prevention of cisplatin-based ...... : a mixed treatment comparison

@en

prefLabel

Prevention of cisplatin-based ...... : a mixed treatment comparison

@ast

Prevention of cisplatin-based ...... : a mixed treatment comparison

@en

P1476

Prevention of cisplatin-based ...... : a mixed treatment comparison

@en

P2093

Fenggang Hou

http://www.w3.org/2001/XMLSchema#string

Hongjia Li

http://www.w3.org/2001/XMLSchema#string

Leizhen Zheng

http://www.w3.org/2001/XMLSchema#string

Qi Shi

http://www.w3.org/2001/XMLSchema#string

Qiqi Le

http://www.w3.org/2001/XMLSchema#string

Shanshan Liu

http://www.w3.org/2001/XMLSchema#string

Shaoqi Zong

http://www.w3.org/2001/XMLSchema#string

Wen Li

http://www.w3.org/2001/XMLSchema#string

P2860

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

Efficacy of aprepitant among patients aged 65 and over receiving moderately to highly emetogenic chemotherapy: a meta-analysis of unpublished data from previously published studies.

[A meta-analysis of aprepitant for prevention of chemotherapy-induced nausea and vomiting].

A phase III study evaluating the safety and efficacy of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting over repeated cycles of chemotherapy.

A randomized phase III study evaluating the efficacy and safety of NEPA, a fixed-dose combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy.

Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy: a randomized dose-ranging pivotal study.

Update and new trends in antiemetic therapy: the continuing need for novel therapies.

Insight in the prediction of chemotherapy-induced nausea.

Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial.

5-Hydroxytryptamine-receptor antagonists versus prochlorperazine for control of delayed nausea caused by doxorubicin: a URCC CCOP randomised controlled trial.

P304

24402-24414

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

meta-analysis

P356

10.18632/ONCOTARGET.8255

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-03-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

299431600

http://www.w3.org/2001/XMLSchema#string

P698

27015550

http://www.w3.org/2001/XMLSchema#string

P932

5029710

http://www.w3.org/2001/XMLSchema#string